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ABSTRACT
Thymidylate synthase (TS) is a crucial target for 5-fluorouracil (5-FU)
in the de novo pathway of pyrimidine synthesis, which is necessary for
DNA synthesis. Thymidine kinase (TK) plays a key role in the comple-
mentary or alternative salvage pathway of pyrimidine synthesis in acute
or pathological tissue stress. In the present study, the activity levels of TS
and TK were determined in 257 primary breast tumors of patients who
received tamoxifen as first-line systemic therapy after diagnosis of ad-
vanced disease. In 155 (60%) responding patients, the median response
duration was 23 months for tumors with low TK activity, 15 months for
tumors with intermediate TK activity, and 13 months for tumors with
high TK activity (P 5 0.003). In Cox multivariate analysis corrected for
classical predictive factors including estrogen receptor and progesterone
receptor, patients with intermediate and high levels of TK activity in their
tumors showed a rapid disease progression (P 5 0.0002) and an early
death (P 5 0.002) after start of tamoxifen treatment. Tumor TS activity
levels were not significantly associated with the efficacy of tamoxifen
treatment. In 121 patients who became resistant to tamoxifen or addi-
tional endocrine treatments and who received 5-FU-containing polyche-
motherapy, tumor TK activity was not significantly related to the efficacy
of chemotherapy. Of the 13 patients with low tumor TS activity, only 1
(8%) responded favorably, whereas 46% (43 of 93) of those with inter-
mediate and 73% (11 of 15) of those with high TS activity responded
(P 5 0.001). In Cox multivariate regression analysis in which TS was the
only significant variable, intermediate and high TS activities were associ-
ated with a slow disease progression (P 5 0.005) and prolonged survival
(P 5 0.016) on chemotherapy. In conclusion, for patients with recurrent
breast cancer, high tumor TK activity is a significant marker of poor
clinical outcome on tamoxifen therapy. Elevated tumor TS activity pre-
dicts a favorable outcome for 5-FU-containing polychemotherapy when
applied after tumor progression on endocrine therapy.
INTRODUCTION
The importance of tumor proliferation in determining response to
chemotherapy and endocrine treatments has been clearly established
in breast cancers. Although patients with a high growth fraction are
likely to benefit from chemotherapy (1), patients with slowly prolif-
erating tumors are likely to benefit from endocrine therapy (2). Py-
rimidine incorporation is a limiting step for DNA replication. In
cellular S phase, two pathways must simultaneously or independently
be involved, the so-called de novo and salvage pathways of pyrimi-
dine synthesis. The proliferation rates of breast cancers have been
analyzed with various methods, such as the S-phase fraction or Ki-67
index, that do not discriminate between the de novo and salvage
pathways of pyrimidine synthesis. Such discrimination would be
important to predict more precisely individual resistance or sensitivity
of the patients. TS3 and TK are key enzymes for pyrimidine synthesis.
In the de novo pathway TS catalyzes the reductive methylation of
dUMP to dTMP, using 5,10-methylene tetrahydrofolate as cofactor. In
the salvage pathway, TK directly catalyzes the phosphorylation of
deoxythymidine released from cells by DNA catabolism (3). Expres-
sion of both enzymes has been associated with proliferation of breast
cancer cells in vitro (4, 5) and with proliferation indices in vivo (6, 7).
Two different forms of TK can be distinguished, a fetal isoform,
which is located in the cytoplasm and at the molecular level is cell
cycle-regulated (8); and an adult isoform, which is located in the
mitochondria. High TK levels have been observed in fast-growing
tissues (9) and in target organs (uterus and prostate) after stimulation
by their corresponding hormones (10, 11). TK expression might
correlate indirectly with neoangiogenesis because the catabolic prod-
ucts of TP, which plays a key role in the supply of TK substrate, are
angiogenic (12). In primary breast tumors, TK levels were related to
the synthesis of the fetal cytosolic isoenzyme and were found to be
elevated in patients who developed a recurrence (13). TK has been
shown to be an independent factor of poor prognosis in node-negative
breast cancer patients not treated with adjuvant therapy (14, 15). TS is
the target for fluoropyrimidines, such as 5-FU. In tumor cells, 5-FU is
converted to 5-fluoro-dUMP, which in the presence of 5,10-methyl-
ene tetrahydrofolate, inactivates TS by formation of a covalent com-
plex with the active site of TS (16). In node-positive breast cancer
patients receiving adjuvant chemotherapy that includes 5-FU, TS was
suggested to be related to a favorable response, whereas high TK
levels were correlated with increased risks of relapse and death (15,
17). The efficacy of endocrine therapy might also be related to the
tumor levels of DNA synthesis enzymes. In nude mouse MCF-7
breast cancer xenografts, tumor TS levels were reduced by treatment
with a pure antiestrogen (18), and in breast cancer cells in vitro the TK
gene has been shown to be under transcriptional control of estrogens
and antiestrogens (4). At present, no studies of patients with advanced
breast cancer are available in which tumor TK and TS levels have
been correlated with the efficacy of systemic endocrine and subse-
quent chemotherapy. TK can be released from the tumor into the
serum, and it has been shown in advanced breast cancer patients
treated with endocrine therapy that serum TK levels were significantly
lowered in the responding patients, whereas in patients who pro-
gressed serum TK levels were increased (19).
High tumor TK activities may be indicative of a poor response to
antimetabolic chemotherapy protocols (15, 17). TS has been sug-
gested to be related to the natural history of the disease (17), and
endocrine therapy merely targets the cell cycle but experimentally
does not select for the de novo and salvage pyrimidine pathways of
DNA synthesis. We therefore wished to study clinically whether the
efficacy of tamoxifen treatment could be related with TK or TS
activity, thus involving some specific pathways uncontrolled by ste-
roid hormone receptors. The aims of the present study were also to
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investigate in patients with advanced breast cancer the relation of
tumor TS expression to the efficacy of polychemotherapy including
5-FU after the occurrence of endocrine resistance.
MATERIALS AND METHODS
Patients and Treatment. The medical ethics committee of the University
Hospital Rotterdam approved our study design. A series of 257 patients with
primary operable breast cancer who underwent resection of their primary
tumors between 1979 and 1991 and who showed a recurrence that was treated
with tamoxifen was selected. The median age of the patients was 62 years
(range, 29–92 years), and 197 patients (77%) were postmenopausal. The
dominant site of relapse was soft tissue in 35 patients (14%), skeletal in 119
patients (46%), and visceral in 103 patients (40%); 178 patients (69%) had a
disease-free interval of .12 months between primary tumor removal and first
recurrence. None of the patients had received neoadjuvant therapy, had been
exposed to hormonal adjuvant treatment, or had been treated with prior
systemic treatment for advanced disease. Only 43 patients had been treated
with adjuvant polychemotherapy (CMF in 23 patients; FAC or 5-FU plus
cyclophosphamide plus epirubicin in 20 patients). Irrespective of ER status, all
257 patients received tamoxifen (40 mg daily) as first-line endocrine therapy
after diagnosis of advanced disease. The median follow-up of patients still
alive after start of tamoxifen treatment was 47 months (range, 4–100 months);
fifty-six patients were still alive at the end of the present study, whereas 201
patients had died. On tamoxifen therapy, tumor progression occurred in 235
patients (91%) during follow-up. Of these patients, 175 were subsequently
treated with one or more additional hormonal agents (mostly high-dose pro-
gestins), and to date, 121 patients have received systemic 5-FU-containing
polychemotherapy (CMF in 78 patients, FAC in 43 patients) after the devel-
opment of hormonal resistance.
The length of PFS was defined as the time from the start of treatment for
advanced disease until the start of next treatment because of progressive
disease or until the time of intercurrent death. All patients were assessed by
standard Union International Contre Cancer criteria for complete and partial
response (objective response). Patients with no change for .6 months (stable
disease) have a OS similar to patients with partial response (20, 21). Therefore,
for overall response, objective response and stable disease were combined.
Tumors and Assays. Tumors were collected and routinely assayed at the
time of surgery for ER and PgR levels according to European Organization for
Research and Treatment of Cancer guidelines, as described previously (22).
When we used 10 fmol/mg of cytosolic protein as cutoff, 84% of the tumors
were classified as ER positive and 74% as PgR positive. For TK and TS assays,
new cytosols were prepared from stored tissues (liquid nitrogen) in European
Organization for Research and Treatment of Cancer buffer containing 4 mM
ATP and 8 mM MgCl2 as has recently been recommended for stability (23).
After it had been established that there was linearity between the activity levels
in serial dilutions of a series of breast cancer cytosols, TK activity levels were
measured with the adapted TK-REA assay (Ref. 23; kits were kindly provided
by AB Sangtec Medical, Bromma, Sweden), and TS activity levels were
measured with a tritium-release assay as described previously (17).
Statistical Analysis. The associations between ER, PgR, TK, and TS were
studied with Spearman rank correlations (rs). The nonparametric Kruskal-
Wallis test was used to study the associations between TS and TK (used as
continuous variable) with tumor size and nodal status at primary surgery and
differentiation grade (used as grouping variables). The relation of response to
therapy was examined with logistic regression analysis. Isotonic regression
analysis (24) was applied to define cutpoints for TK and TS after it had been
established in a test for trend using log-transformed TK and TS activity values
that high TK activity was associated with poor PFS on tamoxifen therapy
(P 5 0.002) and that low TS activity was associated with a more rapid disease
progression on chemotherapy after endocrine resistance (P 5 0.05). Both uni-
and multivariate analyses were performed using the Cox proportional hazards
model. The assumption of proportional hazards was verified graphically.
RHRs were calculated and presented with their 95% CIs. The likelihood ratio
test in the Cox regression models was used to test for differences and for
interactions. Survival curves were generated using the method of Kaplan and
Meier, and the log-rank test for trend was used to examine survival data. All
P values are two-sided.
RESULTS
Levels and Associations. The activity levels of TS and TK in the
257 analyzed tumors were 0–805 fmol [3H]2O/min/mg of protein
(median, 24 fmol [3H]2O/min/mg of protein) for TS and 0–26.4
units/mg of protein (median, 0.41 units/mg of protein) for TK. TS and
TK activity levels were not significantly correlated with the size or
differentiation grade of the tumor or with nodal status at primary
surgery. TS and TK activity levels were negatively correlated
(rs 5 20.26; P , 0.0001), and those of ER and PgR were positively
correlated (rs 5 0.44; P , 0.0001). There was no correlation between
the activity levels of TS or TK with those of ER or PgR. Using
isotonic regression analysis for both TS and TK we defined two
cutpoints, 4 and 84 fmol [3H]2O/min/mg of protein for TS, and 0.16
and 0.93 units/mg of protein for TK.
Response to Tamoxifen Treatment. Of the 257 patients, 155
(60%) responded to tamoxifen. The median duration of response was
23 months in objective responders (n 5 47; range, 3–84 months) and
15 months for stable disease (n 5 108; range, 6–66 months). The ER
status was known for 253 patients; the response rate in patients with
ER-positive tumors was 65% (140 of 216), whereas 35% (13 of 37) of
patients with ER-negative tumors responded favorably. The levels of
TS activity were not significantly related to the rate of response
(median, 24 fmol [3H]2O/min/mg of protein in both responders and
nonresponders) or the length of PFS. A trend could be observed only
between TS activity and the duration of response and the length of OS
after start of tamoxifen treatment. In the 155 responding patients, the
median duration of response was 12 months for tumors with low TS
activity levels (21 patients), 16 months for patients with intermediate
TS activity levels (113 patients), and 23 months for those with high
TS activity (21 patients; P 5 0.08). Compared with patients with low
tumor TS activity, the RHRs were 0.71 (95% CI, 0.48–1.07;
P 5 0.10) for those with intermediate and 0.63 (95% CI, 0.37–1.07;
P 5 0.09) for those with high TS activity, respectively.
In the 155 responding and the 107 nonresponding patients, the
median tumor TK activity levels were 0.34 and 0.53 units/mg of
protein, respectively (P 5 0.08). Compared with the 64 patients with
low tumor TK activity levels (70% response), the 79 patients with
high activity levels showed a poor response to tamoxifen treatment,
with 52% of the patients responding (odds ratio, 0.46; 95% CI,
0.23–0.91; P 5 0.03). In the 114 patients expressing intermediate
tumor TK activity, the response rate was 61% (odds ratio, 0.65; 95%
CI, 0.34–1.25; P 5 0.19; overall P 5 0.08). The amplitude of the
relation of TK activity levels with a poor response rate to tamoxifen
treatment was mostly present in the ER-positive subgroup of patients.
Of 57 ER-positive tumors with low TK activity, 42 (74%) responded,
whereas 37 of 67 (55%) tumors with high TK activity responded. Of
92 ER-positive tumors with intermediate TK activity, 61 (66%) re-
sponded (overall P 5 0.09). The response rates in ER-negative tumors
with low (n 5 7), intermediate (n 5 20), and high (n 5 10) levels of
TK activity were 43, 35, and 30%, respectively (overall P 5 0.86).
Additionally, the duration of response was inversely correlated with
the level of tumor TK activity. In the 155 responding patients, the
median duration of response was 23 months for tumors with low TK
activity (45 patients), 15 months for tumors with intermediate TK
activity (69 patients), and 13 months for tumors with high levels of
TK activity (41 patients; P 5 0.003). In Kaplan-Meier analysis of all
257 patients, when compared with tumors with low TK activity, those
with intermediate and high TK activity showed a shorter PFS
(P 5 0.0001; Fig. 1A) and an earlier death after start of tamoxifen
treatment (P 5 0.007; Fig. 1B). The results of the Cox multivariate
analysis (Table 1) show that, corrected for the classical predictive
factors, TK was an independent variable to predict a poor PFS
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(P 5 0.0002) and OS (P 5 0.002). In a separate multivariate analysis
with ER and PgR included as log-transformed continuous variables
instead of dichotomized variables, the estimators of the effect of
intermediate and high TK activity did not change. Furthermore, when
ER, PgR, and TK were all analyzed as log-transformed continuous
variables, TK remained an independent variable to predict early
disease progression (P 5 0.0005) and death (P 5 0.002). The level of
TS activity did not contribute to the multivariate models (data not
shown). No statistically significant interactions of the activity levels
of TK with those of TS, ER, or PgR in multivariate analyses for PFS
and OS were observed.
Response to Chemotherapy. Of the 121 patients who received
chemotherapy after failure to endocrine treatment(s), 55 (45%) re-
sponded. The median duration of response was 9 months for objective
responders (n 5 22; range, 5–34 months) and 11 months for stable
disease (n 5 33; range, 6–30 months). Irrespective of the type of
treatment (CMF or FAC), there were no significant relationships
between the levels of TK activity and the efficacy or duration of
response to chemotherapy or length of PFS or OS.
Of the 13 patients with low TS activity levels, only 1 (8%) re-
sponded, whereas 43 of 93 (46%) of those with intermediate levels
and 11 of 15 (73%) of the patients with high tumor TS activity levels
responded (P 5 0.001). In Cox univariate analyses of all 121 patients,
when compared with patients with low tumor TS activity levels, those
with intermediate and high levels were associated with a prolonged
PFS (P 5 0.005; Fig. 1C) and an improved OS (P 5 0.016; Fig. 1D).
In Cox multivariate analysis for PFS and OS, TS was the only
significant variable.
DISCUSSION
The benefits of endocrine treatment of breast cancer have been
widely accepted. Nevertheless, ;50% of the tumors do not respond to
(anti)hormonal treatment. Similarly, ;50% do not respond to chem-
otherapy. In the systemic treatment of patients with advanced breast
cancer, the occurrence of acquired therapy resistance in responding
patients is a major problem. Most patients will initially be treated with
endocrine treatment, mainly tamoxifen, and the question remains
Fig. 1. PFS (A) and OS (B) after start of tamoxifen therapy as a function of the level of TK, and PFS (C) and OS (D) on chemotherapy after hormone resistance as a function of
the level of TS. The numbers of patients at risk are indicated. Interm., intermediate; pts., patients.
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which treatment could be most effective after the occurrence of
endocrine resistance. The main aim of the present study was to
investigate whether in the future the knowledge of tumor TK and/or
TS activity status could be helpful in designing individualized treat-
ment strategies. In this report, we focused on the enzymes TS and TK,
which play key roles in the de novo pyrimidine synthesis and the
salvage DNA synthesis pathways, respectively, because specific che-
motherapeutic agents interfere with these pathways.
Evaluation of the clinical importance of DNA-synthesizing en-
zymes in breast cancer showed that TK activity is significantly asso-
ciated with the natural history of the disease. A high prognostic value
was found with respect to disease-free survival and OS (7, 14, 15),
especially in node-negative patients receiving no systemic adjuvant
therapy (14). In an analysis of whether TK and TS are predictive
factors for drug sensitivity in patients receiving 5-FU-containing
adjuvant chemotherapy, our group showed an increase in the average
time to relapse with decreasing levels of TK (15, 17). The subsequent
question regarding the potential association of TK and TS activity
with the efficacy to tamoxifen and chemotherapy in patients with
advanced cancers was investigated in the present study.
In our breast cancer patients, TS and TK activity levels were
log-normally distributed, in agreement with our previous study (17).
In the present study, no positive correlation was found between the
activity levels of TS and TK, suggesting that both pathway of DNA
synthesis may take over each other’s function. In some tumors,
however, synthesis was not clearly predominant in one pathway. Data
obtained in experimental models may support these observations.
Indeed, a coordinated regulation of TK and TS, i.e., a prolonged
decrease in TK activity that coincides with TS inhibition, has been
described in one subtype of murine colon cancer. (25). In contrast, an
uncoordinated variation, i.e., a rapid return of TK activity to the
control level, was observed in another subtype (25). Thus, for tumors
that escape TS blocking by agents such as 5-FU through a fast TK
increase, blocking of both the TS and TK pathways should be tar-
geted.
In the present study, we found no significant correlation between
TK activity and the levels of ER. Only weak negative relationships
(13) or an absence of association (14, 26) have been described
previously, and also by us in specific subgroups of patients (7, 17).
Absence of a correlation with ER was also observed in the present
study for TS, in agreement with previous studies (6, 17, 27). In
MCF-7 breast cancer cells in vitro, it has been shown that the
expression of TK is transcriptionally regulated by estrogen and an-
tiestrogens (4). The lack of an association between TK activity and ER
levels in breast tumors may reflect the heterogeneous nature of breast
tumors or the absence of the transcriptionally regulatory mechanism
in vivo. It may also suggest that in breast cancers additional mecha-
nisms are involved in TK regulation. In this respect, the E2F family of
proteins plays a key role in progression of cells from the late G1 into
S phase. These E2F family members (E2F-1 through E2F-5) regulate
transcription of genes that encode protein products that are required
for DNA synthesis, such as TK, TS, dihydrofolate reductase, and
ribonucleotide reductase (28). On the other hand, c-Myc has contin-
ued to emerge as centerpiece of cancer biology because of its ability
to enhance the activities of specific enzymes involved in DNA me-
tabolism, such as TK, and other metabolic pathways (29). Further-
more, in vitro studies have shown that activation of c-Myc specifically
induced TK mRNA expression and enzyme activity throughout the
cell cycle (30).
We showed that high activity levels of TK, independent of ER and
PgR status, were related with a poor clinical outcome on first-line
tamoxifen therapy. These results are consistent with the reported
benefit of endocrine treatment in slowly proliferating breast cancers
(2). Thus, the inhibitory effect of tamoxifen on tumor growth as a
result of a blockade of ER function has likely been abrogated by the
presence of high TK levels. There is only one very small study in the
literature (12 patients) concerning TK and tamoxifen therapy (26). No
conclusions can be drawn from that study because the patients also
received different kinds of endocrine treatment (26). In our present
study, the patients who failed directly on first-line tamoxifen treat-
ment and those who showed a short duration of response when
initially responding had the highest tumor TK activity levels. In
hormone-refractory patients with relatively high tumor levels of TK,
subsequent 5-FU-containing polychemotherapy failed in the small
group of patients with high tumor TS activity levels. Although this
first report should be interpreted with caution until it has been con-
firmed, this suggests that 5-FU will be effective only when its target
protein is present in sufficient amounts, irrespective of the levels of
TK. No comparable studies involving hormone-resistant advanced
breast cancer patients are available in the literature. In breast cancers
it was shown in a small study that treatment with 5-FU caused an
increase in tumor TS levels and that increased free TS levels may
cause 5-FU resistance (31). In the study of Pestalozzi et al. (27), in
which TS expression was assessed by immunohistochemistry, node-
positive patients with high TS expression demonstrated the most
significant benefit of adjuvant CMF therapy. Furthermore, in rectal
cancers, adjuvant 5-FU-based chemotherapy significantly improved
disease-free survival and OS for patients with high TS levels, whereas
it did not improve prognosis in patients with low levels (32). In other
types of tumors in which TK measurements were not performed
Table 1 Multivariate analysis in tamoxifen-treated patients
PFS OS
P RHRa P RHRa
Age and menopausal status 0.005b 0.014b
Age premenopausalc 0.52 (0.32–0.87) 0.40 (0.23–0.70)
Age postmenopausalc 0.84 (0.72–0.97) 0.94 (0.81–1.10)
Post vs. premenopausal 1.91 (1.02–3.60) 2.23 (1.11–4.49)
Visceral metastasis (vs. skeletal and soft tissue) 0.099 1.26 (0.96–1.65) ,0.0001 1.88 (1.40–2.53)
Disease-free interval (.12 vs. #12 months) 0.002 0.56 (0.41–0.75) ,0.0001 0.45 (0.33–0.62)
ER/PgR (1/1 vs. others)d 0.008 0.66 (0.49–0.89) ,0.0001 0.43 (0.31–0.58)
TK 0.0002e 0.002e
TK-intermediate vs. TK-low f 1.47 (1.05–2.07) 1.69 (1.17–2.44)
TK-high vs. TK-low f 2.15 (1.50–3.09) 1.91 (1.29–2.83)
a 95% CI in parentheses. The final multivariate models included 250 patients.
b Age and menopausal status combined.
c Tested in decades, separately for pre- and postmenopausal patients.
d 1/1, ER and PgR $10 fmol/mg of protein (n 5 180) vs. combined one (n 5 24) or both ,10 fmol/mg of protein (n 5 46).
e TK-intermediate and TK-high combined.
f TK-low, #0.16 units/mg of protein; TK-intermediate, .0.16–0.93 units/mg of protein; TK-high, .0.93 units/mg of protein.
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simultaneously, such as colorectal cancer (33, 34), gastric cancer (34),
and head and neck cancer (35), higher tumor TS levels were almost
uniformly found in nonresponding patients or were associated with
poor clinical outcome.
Concerning TK and chemotherapy, in the small study of Zhang et
al. (26), higher levels were found in the tumors of 17 responding
patients compared with those of 28 patients who did not respond.
However, these data are difficult to interpret because the investigators
included predominantly ER-negative patients who received a very
heterogeneous mixture of chemotherapy regimens and who were not
yet hormone refractory. In the present study, in hormone-refractory
patients who already had the highest levels of tumor TK activity, the
level was not further related to the efficacy of subsequent chemother-
apy. Previously, we showed that in patients with primary breast cancer
who were treated with adjuvant CMF or FAC, high TK activity levels
were associated with a poor prognosis, which suggested that high
levels of TK were associated with failure of antimetabolic chemother-
apy protocols (15, 17). It thus may be a selective factor for innovative
treatment protocols including, e.g., taxanes. In our present study, we
showed that for patients with recurrent breast cancer, high tumor TK
activity levels are associated with a poor efficacy of tamoxifen ther-
apy. We also showed for the first time a small subgroup of patients
with high tumor TS activity who responded favorably to polychemo-
therapy that included 5-FU after they had become hormone refractory.
Our results suggest that in the future, treating patients individually
based on the tumor levels of TK and TS may be considered. In
addition, for hormone-refractory patients, administration of 5-FU or
new TS inhibitors, which presently are under clinical evaluation,
could be considered for tumors with high TS activity levels, whereas
treatment with other drugs, such as taxanes, could be more effective
in patients with high tumor TK activity levels but a less active de novo
pyrimidine synthesis pathway.
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